China Medical System Holdings
China Medical System Holdings is an intergraded and profitable pharmaceutical company, which develops, manufactures, sells and markets prescription drugs and medical devices in China.
See more information about China Medical System Holdings
China Medical System Holdings climbs after reporting strong net profit growth
China Medical System Holdings (AIM:CMSH) surged more than 15% in trading after the company reported solid full year results for the 12 months ended 31 December 2008.
Financial highlights included a 40% jump in sales to US$72.6 million, 72% surge in net profits to $15 million and 14% increase in cash and cash equivalents to US$20.1 million. Earnings per share rose 59% to 31.6 cents per share (19.9 cents in 2007). The full year dividend increased by 50% to 15 cents per share.
All of China Medical System Holdings existing products recorded strong growth, included anti-depressant product, Deanxit and primary liver cancer drug GanFuLe.
Commenting on the results, Mr Kong Lam, Chairman & CEO said, “I am delighted to report on a second outstanding year for CMS as a public company despite the challenging economic environment seen domestically and globally. We have achieved sustained and steady growth in sales and profits, and I am pleased that, in line with our growth strategy, we have also made solid progress towards expanding our product portfolio as well as advancing our in-house R&D novel compounds.”
Other China Medical System Holdings news
- China Medical System seals exclusive license to sell Bioflor diarrhea drug in China
2010-02-03 - China Medical System Holdings full year revenues rise 32%
2010-01-13
